Yan, ChaoLiu, DegangLi, LiweiWempe, Michael F.Guin, SunnyKhanna, MayMeier, JeremyHoffman, BrentonOwens, CharlesWysoczynski, Christina L.Nitz, Matthew D.Knabe, Eric W.Brautigan, David L.Paschal, Bryce M.Schwartz, Martin A.Jones, DavidRoss, DavidMeroueh, Samy O.Theodorescu, Dan2016-03-142016-03-142014-11-20Yan, C., Liu, D., Li, L., Wempe, M. F., Guin, S., Khanna, M., … Theodorescu, D. (2014). Discovery and characterization of small molecules that target the Ral GTPase. Nature, 515(7527), 443–447. http://doi.org/10.1038/nature137130028-0836https://hdl.handle.net/1805/8846The Ras-like GTPases RalA and B are important drivers of tumor growth and metastasis. Chemicals that block Ral function would be valuable as research tools and for cancer therapeutics. Here, we used protein structure analysis and virtual screening to identify drug-like molecules that bind a site on the GDP-form of Ral. Compounds RBC6, RBC8 and RBC10 inhibited Ral binding to its effector RalBP1, Ral-mediated cell spreading in murine fibroblasts and anchorage-independent growth of human cancer cell lines. Binding of RBC8 derivative BQU57 to RalB was confirmed by isothermal titration calorimetry, surface plasma resonance and 15N-HSQC NMR. RBC8 and BQU57 show selectivity for Ral relative to Ras or Rho and inhibit xenograft tumor growth similar to depletion of Ral by siRNA. Our results show the utility of structure-based discovery for development of therapeutics for Ral-dependent cancers.en-USPublisher PolicyDrug Screening Assays, AntitumorMolecular Targeted TherapySmall Molecule Librarieschemistrypharmacologyral GTP-Binding Proteinsantagonists & inhibitorsArticle